MHRAsafety guidance72% confidence
Clinical trials for medicines: ending a clinical trial
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to BioNTech SE.
Regulatory Analysis
Guidance on the process for ending a clinical trial.
Supporting Context
- Therapeutic area
- Infectious Disease · Vaccine
- Sub-indication
- General
Related signal: BioNTech's mRNA Mpox Vaccine Candidate Enters Clinical Trial Phase